fda bpc 157 safety concerns compounding Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling fda warning bpc-157 unapproved peptide
Description
A potential contributor to these different functional outcomes is the timing with which these groups regenerated oligodendrocytes
The peptide's ability to simultaneously modulate multiple pathways involved in tissue repair and cellular protection distinguishes it from single-target therapeutic agents and may explain its consistent benefits across diverse injury models
[1] The molecular formula is CHNOS with a molecular weight of approximately 1815.1 g/mol (PubChem CID 71300630)
doi: 10.1016/j.expneurol.2017.05.010
